Pulse Biosciences, Inc. (PLSE) Reports Q3 Loss of $0.64
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pulse Biosciences Quarterly Investor Conference Call
October 30, 2018 4:03 PM EDTConference call today at 1:30 p.m. PDT / 4:30 p.m. EDT
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation (NPS) platform, today reported recent corporate developments and financial results for the three- and nine-month periods ended September 30, 2018.
Recent Developments
Completion of enrollment and patient treatments in the Companys NPS clinical study for the treatment of Sebaceous Hyperplasia (SH) Study enrollment and patient... More